Study of a new drug combination for residual TNBC after initial treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (TNBC) that did not completely disappear after chemotherapy and immunotherapy (pembrolizumab) before surgery.
- You received the standard neoadjuvant therapy (KEYNOTE-522 regimen) and had surgery to remove all visible cancer, but some cancer remained in the breast or lymph nodes.
- You are well enough to continue immunotherapy (pembrolizumab) after surgery, and your surgery was within the last 16 weeks.
- You have not had prior treatment with a TROP2-targeted antibody-drug conjugate (a type of targeted cancer therapy) or a topoisomerase inhibitor drug.
- Your cancer has not spread to other parts of the body, and you have no other active cancers or serious medical conditions (like severe heart disease, inflammatory bowel disease, or autoimmune disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.